entity

APRIL

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about APRIL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

14Connections
0Hypotheses
0Analyses
14Outgoing
0Incoming

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

AAN 2026 — American Academy of Neurology Annual Meeting

event · 756 words

RNA Therapeutics for Neurodegeneration Investment Landscape

investment · 3955 words

Idorsia Pharmaceuticals Ltd.

company · 3906 words

tudca-udca-neurodegeneration

therapeutic · 3718 words

Tau Pathology

mechanism · 3310 words

nct06365190-rtms-pd

clinical_trial · 3270 words

Outgoing (14)

TargetRelationTypeStr
Heparan Sulfate Proteoglycansbindscompound0.95
HEPARAN SULFATE PROTEOGLYCANSbindsprotein0.95
Atherosclerosisinhibitsdisease0.95
Heparan Sulfate Proteoglycansinteracts_withreceptor0.92
Atherosclerosis Progressioninhibitsprocess0.90

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found